Skip to main content
Figure 2 | Trials

Figure 2

From: Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

Figure 2

H5N1 haemagglutination inhibition antibody response against A/Vietnam/1194/2004. Vaccination groups are: 1xH5N1-AS, single dose of the AS03A-adjuvanted vaccine; 1xH5N1, single dose of the non-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine. Seroconversion rate (SCR) was defined as the percentage of participants with either a pre-vaccination titre <1:10 and a post-vaccination titre ≥1:40, or a pre-vaccination titre ≥1:10 and a ≥4-fold increase in post-vaccination titre; and seroprotection rate (SPR) was defined as the percentage of participants with a haemagglutination inhibition titre ≥1:40. GMT, geometric mean titre. Error bars indicate the 95% confidence intervals. Post-vaccination = day 42 (data also shown in [13]). Post-vaccination results are shown for the according-to-protocol immunogenicity cohort (1xH5N1-AS: N =152, 1xH5N1: N =54, 2xH5N1-AS: N =145, 2xH5N1: N = 44); month 12 and month 24 results for the month 24 according-to-protocol persistence cohort (1xH5N1-AS: N = 86, 1xH5N1: N = 37, 2xH5N1-AS: N =81, 2xH5N1: N = 24); N = maximum number of participants with available results.

Back to article page

Trials

ISSN: 1745-6215